EcoDrugPlus

Ribosomal Protein L12

Ensembl ID : ENSBTAG00000006963
Gene Symbol: RPL12
15 Enzyme and pathways 4 Cross references
199 Possible Orthologues:

Ribosomal Protein L13

Ensembl ID : ENSBTAG00000012044
Gene Symbol: RPL13
15 Enzyme and pathways 5 Cross references
249 Possible Orthologues:

Ribosomal Protein L14

Ensembl ID : ENSBTAG00000002038
Gene Symbol: RPL14
15 Enzyme and pathways 5 Cross references
302 Possible Orthologues:

Ribosomal Protein L15

Ensembl ID : ENSBTAG00000033080
Gene Symbol: RPL15
15 Enzyme and pathways 4 Cross references
210 Possible Orthologues:

Ribosomal Protein L18

Ensembl ID : ENSBTAG00000015388
Gene Symbol: RPL18
15 Enzyme and pathways 5 Cross references
294 Possible Orthologues:

Ribosomal Protein L18a

Ensembl ID : ENSBTAG00000015831
Gene Symbol: RPL18A
15 Enzyme and pathways 5 Cross references
192 Possible Orthologues:

Ribosomal Protein L19

Ensembl ID : ENSBTAG00000002060
Gene Symbol: RPL19
15 Enzyme and pathways 5 Cross references
248 Possible Orthologues:

Ribosomal Protein L22

Ensembl ID : ENSBTAG00000014423
Gene Symbol: RPL22
15 Enzyme and pathways 5 Cross references
253 Possible Orthologues:

Ribosomal Protein L23

Ensembl ID : ENSBTAG00000003229
Gene Symbol: RPL23
15 Enzyme and pathways 5 Cross references
221 Possible Orthologues:

Ribosomal Protein L24

Ensembl ID : ENSBTAG00000013461
Gene Symbol: RPL24
15 Enzyme and pathways 5 Cross references
226 Possible Orthologues:

Ribosomal Protein L26

Ensembl ID : ENSBTAG00000012344
Gene Symbol: RPL26
15 Enzyme and pathways 4 Cross references
230 Possible Orthologues:

Ribosomal Protein L27

Ensembl ID : ENSBTAG00000017441
Gene Symbol: RPL27
15 Enzyme and pathways 5 Cross references
199 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).